Welcome to our dedicated page for Viking Therapeutics SEC filings (Ticker: VKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Viking Therapeutics’ latest SEC disclosures can feel like decoding a clinical protocol. Each 10-K details multiple metabolic drug candidates, while surprise 8-K trial updates often move VKTX shares overnight. If you have ever asked “Where can I find Viking Therapeutics’ quarterly earnings report 10-Q filing?” or “How do I follow Viking Therapeutics insider trading Form 4 transactions?”, this page is built for you.
Stock Titan’s AI-powered analysis turns dense biotech language into clear insights. Our engine highlights R&D spend trends, flags cash-runway warnings, and links every Viking Therapeutics Form 4 insider transactions real-time alert to market-moving events. Need the story behind a sudden secondary offering? We tag S-3 and 424B filings automatically. Looking for the next catalyst? 8-K material events are explained alongside milestone timelines. It’s SEC compliance information, but in plain English—Viking Therapeutics SEC filings explained simply.
All VKTX documents—10-K annual report, 10-Q updates, proxy statement executive compensation tables, and insider Form 4s—arrive the moment EDGAR posts them. Use AI summaries to compare segments, or drill into trial spending with one click. Typical use cases include:
- Monitoring Viking Therapeutics executive stock transactions Form 4 before Phase 2 readouts
- Reviewing Viking Therapeutics annual report 10-K simplified to gauge dilution risk
- Running a Viking Therapeutics earnings report filing analysis to track cash burn versus guidance
- Understanding Viking Therapeutics SEC documents with AI to spot 8-K material events explained
Whether you are an analyst, portfolio manager, or biotech enthusiast, our real-time feed ensures you never miss a Viking Therapeutics quarterly earnings report 10-Q filing or a pivotal proxy vote. Make informed decisions faster—no PhD required.
Viking Therapeutics (VKTX) COO reported Form 4 activity. On October 27, 2025, 11,117 shares were acquired at $0 upon vesting of performance RSUs tied to non-financial goals. On October 28, 2025, 6,185 shares were sold at a weighted average price of $35.0027 to cover tax withholding related to the vesting.
Following these transactions, the executive directly beneficially owned 382,467 shares. The sales were executed in multiple trades between $34.69 and $35.40.
Viking Therapeutics (VKTX) reported insider activity by a director on 10/27/2025. The director exercised stock options for 60,000 shares in total—16,000 at an exercise price of $4.48, 22,000 at $5.80, and 22,000 at $4.88.
On the same date, the director sold 60,000 shares at a $35.5713 weighted-average price, with sales occurring between $35.02 and $35.94. Following these transactions, the director beneficially owned 30,000 shares directly.
Option origins and terms disclosed include grants dated 01/02/2019 (expiring 01/02/2028), 01/04/2022 (expiring 01/04/2031), and 01/03/2023 (expiring 01/03/2032), each corresponding to the exercised amounts listed above.
Viking Therapeutics (VKTX) President & CEO and director reported equity activity on Form 4. On 10/27/2025, 70,084 shares of common stock were acquired at $0 upon vesting of performance RSUs tied to non-financial goals. On 10/28/2025, 38,989 shares were sold at a $35.0079 weighted average solely to satisfy tax withholding, with trades ranging $34.66–$35.48. Following the transactions, direct beneficial ownership stands at 2,419,109 shares.
Viking Therapeutics (VKTX) reported a Form 4 for its Chief Financial Officer. On 10/27/2025, the CFO acquired 11,117 shares of common stock at $0 upon vesting of performance RSUs tied to non-financial goals. On 10/28/2025, 6,185 shares were sold at a weighted average price of $35.0009 to satisfy tax withholding related to that vesting.
Following these transactions, the CFO directly holds 173,592 shares. Shares briefly stood at 179,777 after the vesting before the tax-related sale.
Viking Therapeutics (VKTX) filed its Q3 2025 report, showing higher R&D as programs advanced and a wider loss. For the quarter, net loss was $90.8 million, or $0.81 per share, driven by research and development expense of $89.9 million and general and administrative expense of $8.6 million. There was no revenue.
Liquidity remained strong with cash and cash equivalents of $100.4 million and short‑term investments of $614.2 million as of September 30, 2025. For the nine months, the company used $193.4 million in operating cash. Stockholders’ equity was $713.0 million.
Capital markets tools are in place: an S‑3 shelf effective July 2023, ATM capacity remaining up to $151.9 million, and a $250.0 million repurchase program authorized in February 2025 (no repurchases in Q3). The March 2024 offering provided $597.1 million net proceeds. Shares outstanding were 113,036,344 as of October 15, 2025.
Operationally, Viking entered multi‑year manufacturing agreements for VK2735 with prepayments from 2025 to 2028 credited against future orders. A subsequent lease amendment expands headquarters space, with $63,000 monthly base rent starting on the later of substantial completion or April 1, 2026.
Viking Therapeutics (VKTX) furnished an 8-K announcing it issued a press release reporting financial results for the third quarter ended September 30, 2025 and providing a corporate update. The press release is included as Exhibit 99.1. The company notes that the information under Item 2.02 is furnished, not filed, under the Exchange Act.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
